NEWS & EVENTS

Latest news and upcoming events

Ysios Capital ESG Report
20 Nov 2024

Ysios Capital ESG Report

Upcoming events

  • Bio-Neuroscience
    25 - 27 February 2025
    Amsterdam

    download

  • 18th Annual European Life Sciences CEO Forum
    26 - 27 February 2025
    Zurich

    download
Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia<
17 Dec 2024

Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia

Clinical trial in patients anticipated to begin in 2025
SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease<
12 Dec 2024

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

Phase 1/2 ASTRA study set to begin in the first half of 2025.
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy<
11 Dec 2024

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025.
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society<
06 Dec 2024

Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society

FDA granted RMAT designation in 2024; pivotal trial planned for 2H 2025
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing<
28 Nov 2024

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx
Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First- in-class ADC Pipeline<
25 Nov 2024

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First- in-class ADC Pipeline

Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept
AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences<
25 Nov 2024

AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences

The HTI vaccines have shown promising results in phase 1 and phase 2 clinical trials
Ysios Capital ESG Report<
20 Nov 2024

Ysios Capital ESG Report

A milestone reflecting the firm’s deep commitment to responsible and sustainable investment.
Xeltis announces FDA Breakthrough Device Designation for aXessTM and first patient treated in US pivotal trial<
14 Nov 2024

Xeltis announces FDA Breakthrough Device Designation for aXessTM and first patient treated in US pivotal trial

Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages over current therapies
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights<
12 Nov 2024

Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

Strong Cash Position Expected to Support Operations into 2H 2026

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Для тех, кто ищет безопасную и удобную платформу, Joycasino официальный сайт станет лучшим выбором благодаря акционным предложениям и огромному выбору игр. кракен ссылкакракен ссылка кракен даркнеткракен даркнет